Glenn Mattes has been working in the pharmaceutical industry for over 30 years. He has held senior global leadership positions at Rhone Poulenc Rorer, Centocor and Johnson & Johnson. At J&J, he was Global President of Tibotec Therapeutics where he lead J&J’s oncology and infectious disease franchises that included Procrit® and Doxil®. During his career, he has managed a number of product franchises that achieved market leadership and sales in excess of $1 Billion including Taxotere (RPR) and Remicade (Centocor). In the most recent 5 years, Glenn has become a serial entrepreneur working with public and private clinical and pre-clinical stage companies in CEO, Board member or executive chair positions. He has successfully raised funding for these companies while managing their growth and market opportunities.
|Board of Directors|